Compare FWONK & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FWONK | WST |
|---|---|---|
| Founded | 1950 | 1923 |
| Country | United States | United States |
| Employees | 1674 | N/A |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 18.5B |
| IPO Year | N/A | 2004 |
| Metric | FWONK | WST |
|---|---|---|
| Price | $89.48 | $329.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $110.88 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 1.6M | 588.2K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | N/A | ★ 1.49 |
| EPS | N/A | ★ 1.92 |
| Revenue | N/A | ★ $2,886,900,000.00 |
| Revenue This Year | $24.56 | $6.76 |
| Revenue Next Year | $5.52 | $6.22 |
| P/E Ratio | ★ $107.00 | $172.62 |
| Revenue Growth | N/A | ★ 1.95 |
| 52 Week Low | $80.15 | $206.80 |
| 52 Week High | $109.36 | $336.82 |
| Indicator | FWONK | WST |
|---|---|---|
| Relative Strength Index (RSI) | 52.41 | 61.89 |
| Support Level | $82.32 | $253.53 |
| Resistance Level | $91.70 | $333.85 |
| Average True Range (ATR) | 2.61 | 7.39 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 69.30 | 72.43 |
Liberty Media Corp along with its subsidiaries is engaged in the media and entertainment industries in North America and the United Kingdom. The company owns interests in a high-quality portfolio of assets across the media, entertainment and sports industries. It operates in two reportable segment Formula 1 and MotoGP. It generates majority of its revenue from the Formula 1 segment. The company derives its maximum revenue from United Kingdom.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.